Old Web
English
Sign In
Acemap
>
authorDetail
>
Surya Vangala
Surya Vangala
Advaxis
Medicine
Pembrolizumab
Immunotherapy
Antigen
Oncology
6
Papers
3
Citations
0
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
360 A phase 1 study of an Off-the-Shelf, multi-neoantigen vector (ADXS-503) alone and in combination with pembrolizumab in subjects with metastatic non-small cell lung cancer (NSCLC)
2020
Journal for ImmunoTherapy of Cancer
Jonathan H. Goldman
Thomas E. Stinchcombe
Gregory J Gerstner
Missak Haigentz
Surya Vangala
Megan Parsi
Victor Kabala
Dinesh Simkhada
Andres A. Gutierrez
Suresh S. Ramalingam
Show All
Source
Cite
Save
Citations (0)
A phase I study of ADXS-503 alone and in combination with pembrolizumab in subjects with metastatic squamous or non-squamous non-small cell lung cancer (NSCLC).
2020
Journal of Clinical Oncology
Suresh S. Ramalingam
Tom Stinchcombe
Gregory James Gerstner
Missak Haigentz
Surya Vangala
Megan Parsi
John W. Heyburn
Victor Kabala
Tuhina Prasad
Andres A. Gutierrez
Jonathan Wade Goldman
Show All
Source
Cite
Save
Citations (1)
KEYNOTE-046 (Part B): Effects of ADXS-PSA in combination with pembrolizumab on survival in metastatic, castration-resistant prostate cancer patients with or without prior exposure to docetaxel.
2020
Journal of Clinical Oncology
Mark N. Stein
Lawrence Fong
Anthony E. Mega
Elaine Tat Lam
John W. Heyburn
Andres A. Gutierrez
Megan Parsi
Surya Vangala
Naomi B. Haas
Show All
Source
Cite
Save
Citations (2)
1